Impacts of medical and non-medical cannabis on the health of older adults: Findings from a scoping review of the literature

PLoS ONE, Journal Year: 2023, Volume and Issue: 18(2), P. e0281826 - e0281826

Published: Feb. 17, 2023

Background Cannabis legalization has enabled increased consumption in older adults. Age-related mental, physical, and physiological changes may lead to differences effects of cannabis adults compared younger individuals. Objective To perform a scoping review map the evidence regarding health use for medical non-medical purposes Methods Electronic databases (MEDLINE, Embase, PsycINFO, Cochrane Library) were searched systematic reviews (SRs), randomized controlled trials (RCTs) non-randomized/observational studies (NRSs) assessing associations (medical or non-medical) ≥ 50 years age. Included met age-related inclusion criteria involved priori identified conditions common among Records screened using liberal accelerated approach data charting was performed independently by two reviewers. Descriptive summaries, structured tables, effect direction plots bubble used synthesize study findings. Findings From 31,393 citations, 133 publications describing 134 unique (26 SRs, 36 RCTs, 72 NRSs) included. Medical had inconsistent therapeutic specific patient (e.g., end-stage cancer, dementia), with number suggesting possible benefits while others found no benefit. For cannabis, harmful outnumbered beneficial, RCTs reported more negative than NRSs. associated greater frequencies depression, anxiety, cognitive impairment, substance problematic use, accidents/injuries, acute healthcare use. Studies often small, did not consistently assess harms, adjust confounding. Discussion The are within conditions. adults, generally, available suggests be mental issues, benefit-to-risk ratio is unclear. balanced assessment harms guide appropriate public messaging balance marketing pressures

Language: Английский

---

The Effects of Stigma: Older Persons and Medicinal Cannabis

Qualitative Health Research, Journal Year: 2024, Volume and Issue: 34(8-9), P. 717 - 731

Published: Feb. 2, 2024

Cannabis has long been stigmatized as an illicit drug. Since legalization in Canada for both medical and recreational purposes, older adults’ cannabis consumption increased more than any other age group. Yet, it is unclear how the normalization of impacted perceptions stigma adults consuming medicinally. Qualitative description was used to elucidate experiences Canadians aged 60+ related their medicinal purposes. Data collection involved semi-structured interviews. analysis examined participants managed use. Perceived evident many participants’ descriptions past present, influenced they accessed consumed comfort discussing its use with healthcare providers. Participants employed several distinct strategies managing stigma—concealing, re-framing, re-focusing, proselytizing. Findings suggest that while becoming increasingly normalized among adults, persists continues shape experiences. A culture shift needs occur providers so are educated about willing discuss possibilities adults. Otherwise, may seek advice from or non-medical sources. Healthcare require education cannabis, can better advise regarding

Language: Английский

---

Detecting and understanding potential stigma among medical cannabis users in Germany

BMC Public Health, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 5, 2025

Language: Английский

---

Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment

Cancers, Journal Year: 2023, Volume and Issue: 15(7), P. 2119 - 2119

Published: April 1, 2023

The application of cannabis products in oncology receives interest, especially from patients. Despite the plethora research data available, added value curative or palliative cancer care and possible risks involved are insufficiently proven therefore a matter debate. We aim to give recommendation on position clinical by assessing recent literature. Various types products, characteristics, quality pharmacology discussed. Standardisation is essential for reliable reproducible quality. oromucosal/sublingual route administration preferred over inhalation drinking tea. Cannabinoids may inhibit efflux transporters drug-metabolising enzymes, possibly inducing pharmacokinetic interactions with anticancer drugs being substrates these proteins. This enhance cytostatic effect and/or drug-related adverse effects. Reversely, it enable dose reduction. Similar likely used symptom management treating pain, nausea, vomiting anorexia. Cannabis usually well tolerated improve life patients (although not unambiguously proven). combination immunotherapy seems undesirable because immunosuppressive action cannabinoids. Further warranted scientifically support (refraining from) using cancer.

Language: Английский

---

Lessons from 20 years of medical cannabis use in Canada

PLoS ONE, Journal Year: 2023, Volume and Issue: 18(3), P. e0271079 - e0271079

Published: March 23, 2023

Canada was one of the first countries to regulate medical use cannabis. However, literature on Canada's cannabis program is limited.We administrative data from program, and licensed vendor catalog describe a) participation patients, physicians, vendors in its inception 1999 2021, b) trends consumption, prices potency. We also national surveys conducted over last several decades estimate regular (medical or otherwise) how it changed during access regimes.In 2001, Canadian government granted those with physician-documented evidence a severe health problem that could not be managed using conventional therapies. Most patients accessed grown under personal production license. By 2013, authorized daily dosages were very high. In 2014, government, concerned illegal diversion, required purchased commercial grower; banned. Physicians given responsibility for authorizing patient access. To fill regulatory void, physician bodies imposed their own prescribing restrictions. After these changes, number physicians who willing support markedly decline but participating sharply increased. Medical varied by province-rates generally lower provinces stricter regulations prescribing. varieties oil available sale are now high CBD low THC. Dry varieties, conversely, tend THC CBD. Inflation adjusted most have declined time. find rates increased after 2014 policy regime. The fraction Canadians again 2018 legalization recreational cannabis; at same time, declined.The implications outcomes changes remains an important area future research.

Language: Английский

---

Cannabidiol for behavior symptoms in Alzheimer’s disease (CANBiS-AD): a randomized, double-blind, placebo-controlled trial

International Psychogeriatrics, Journal Year: 2024, Volume and Issue: 36(12), P. 1270 - 1272

Published: April 8, 2024

An abstract is not available for this content. As you have access to content, full HTML content provided on page. A PDF of also in through the 'Save PDF' action button.

Language: Английский

---

Older adults experiences of using recreational cannabis for medicinal purposes following legalization

International Journal of Drug Policy, Journal Year: 2022, Volume and Issue: 108, P. 103812 - 103812

Published: Aug. 2, 2022

Language: Английский

---

Exploring women’s intentions to seek medicinal cannabis prescriptions in New Zealand using the theory of planned behaviour

Drugs Education Prevention and Policy, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 13

Published: March 13, 2025

Language: Английский

---

Education, Training, and Perceptions of Physician Competency Among Medical Cannabis Patients in Israel

Complementary Therapies in Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 103172 - 103172

Published: April 1, 2025

Language: Английский

---

Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis

JAMA Neurology, Journal Year: 2025, Volume and Issue: unknown

Published: April 14, 2025

Importance Cannabis use is associated with short-term memory impairment and long-term changes in brain structure; however, little known about whether disordered cannabis an increased risk of a dementia diagnosis. Objective To investigate the association between emergency department visits or hospitalizations (acute care encounters) due to future Design, Setting, Participants Population-based, retrospective, matched cohort study using health administrative data from Ontario, Canada, 2008 2021 (with follow-up until 2022) including all individuals aged 45 105 years living Ontario who were eligible did not have diagnosis at entry (2 620 083 excluded). Exposure Individuals incident acute use, defined International Classification Diseases Related Health Problems, Tenth Revision coding. Main Outcomes Measures We used cause-specific adjusted hazard models compare new diagnoses (from validated algorithm) (1) all-cause (excluding cannabis), (2) general population, (3) alcohol use. Results The included 6 086 794 individuals, whom 16 275 (0.3%) had (mean age, 55.2 [SD, 8.3] years; 60.3% male). Annual rates 5.0-fold 64 10.16 50.65 per 100 000) 26.7-fold 65 older 0.65 16.99 2021. 1.5-fold 3.9-fold within 5 relative population same age sex, respectively (absolute diagnosis: 5.0% for cannabis-related care, 3.6% 1.3% population). After adjustment sociodemographics chronic conditions, remained elevated those (adjusted ratio [aHR], 1.23; 95% CI, 1.09-1.39) (aHR, 1.72; 1.38-2.15). lower than 0.69; 0.62-0.76). Conclusions Relevance severe enough require hospital-based compared population. These findings important implications considering increasing among adults.

Language: Английский

---